Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
about
Bcl-2 antagonists: a proof of concept for CLL therapyEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesConformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind LigandsBM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivoBcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.The role of HTS in drug discovery at the University of Michigan.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.New targets for the treatment of follicular lymphoma.ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer.Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancerASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.The essential role of evasion from cell death in cancer.RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maInhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerS6K1 inhibition enhances the apoptotic cell death of breast cancer cells in response to Bcl-2/Bcl-xL inhibition by the downregulation of survivinRapamycin rescues ABT-737 efficacy in small cell lung cancerBH3-only proteins in apoptosis at a glanceHuman platelet lysate improves human cord blood derived ECFC survival and vasculogenesis in three dimensional (3D) collagen matricesCombination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Novel therapeutic approaches for small cell lung cancer: the future has arrivedCopy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer.Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regressionTargeted therapies in small cell lung cancerCombination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
P2860
Q26823996-82E281B7-F5BD-45AA-A312-1BAECF8AEEAEQ26999187-D30A27FC-FACD-4046-83D7-34FC06A2BAABQ27657282-0D3F258A-1207-4245-8A61-076865CFA024Q28539452-3B5C4C24-006D-411B-BB03-FC89A5443BDFQ30495553-941FA937-BCF2-4187-BD19-1F166AFE08A3Q31147980-FE9B133B-8E9C-4351-BE0C-6A06AF43EC4FQ33393931-26BB6498-A6DA-46A0-B6EA-8810232C7C0AQ33400716-BB69D5D1-FA33-4FD2-ADDF-D8145D29F674Q33587396-129D4171-2628-494B-93E8-321DE831A56CQ33842714-15B6287F-1CEE-43DE-8B19-5AD2F5C180E7Q33875700-B2C4B909-0805-4BCF-A828-856EFC18184FQ33988315-2BF68286-48B9-4E80-9739-82F0429473F3Q34301314-9D9A0806-9FBD-4AC5-8E24-6B62E464EADFQ34363479-247A835B-E732-4DB0-A8BD-C55C6BF74FA0Q34383742-A383CF05-AB60-42E0-B0A0-102FAA1D1BD1Q35083049-AA0CEBA4-5BB8-46A5-95FD-9C010495E02EQ35170413-DA02EF59-A86A-4941-936C-AB718B51B400Q35212727-3BED3F77-0679-4120-9368-40217CC2EDF2Q35220218-01888577-5E5D-4FCD-A95C-AF51C80FB995Q35434111-48ACCF76-A124-4F07-989E-74B4D91A0087Q35543223-8B4FFC7F-8809-423D-A586-358DC8B013C2Q35579660-CC3A2FD3-84C2-4B99-B6DA-3A9C33931259Q35605318-886BE2B4-F58C-4952-BA29-69EC202BB312Q35696221-BB1FE462-B14F-471F-91A0-D6E6AC58E1CAQ35835203-B0C09198-CB57-4D1D-BA1C-1F7CF74F6479Q35870533-306E3AB7-FD1D-4DE9-840A-768B17D59937Q35878431-8D29CFD3-18EA-407B-B766-96DC86AE81A7Q35883875-A4FBF7D8-10FA-45CF-B593-618D6D987BCBQ35958188-56125092-8828-409A-B29B-8F320767C0EEQ35964716-190CC277-28FB-4BAF-A44A-D592588F9F70Q36035933-E20ECC15-FF50-4DF3-B106-3DBF9BD004CEQ36084288-DB98CDB8-DA6B-4BB3-B9BC-C5FC12D2CD80Q36121767-C3DE5F10-3115-448C-B7F1-B0541926D8ABQ36172748-168009E9-2F7C-4685-BCE3-352C8308875EQ36173303-8078E192-03EB-4B71-91B6-FF9D78D2059BQ36390326-4799ED53-13A4-4FC5-8036-9478978448E9Q36475811-C660224B-C4B6-467A-B9D8-CF30E08C8A56Q36481165-A251EF7C-EF15-4ED0-BF95-EAE665482416Q36541458-462D1F7D-7F35-434C-A208-51E863F343C6Q36561621-FFD231B3-2CC9-4A1B-AB8B-E60F37C89480
P2860
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@ast
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@en
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@nl
type
label
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@ast
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@en
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@nl
prefLabel
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@ast
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@en
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@nl
P2093
P1476
Activity of the Bcl-2 family i ...... lung cancer xenograft models.
@en
P2093
Alex R Shoemaker
Anatol Oleksijew
Baole Wang
Christin Tse
David J Frost
Debra Ferguson
Jacqueline M O'Connor
Jessica Adickes
Kennan Marsh
P304
P356
10.1158/1078-0432.CCR-07-4622
P407
P577
2008-06-01T00:00:00Z